Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
What: Shares of biopharmaceutical company MannKind
So what: MannKind is approaching a decision date for its inhaled insulin product, and investors are making bets on what the result will be. Option activity was up today and volume was nearly seven times average, and I expect more volatility through the end of the year.
Now what: If Afrezza is the drug MannKind thinks it can be, this stock will shoot higher to end the year, and investors who own the stock will make a killing on the stock. But the Food and Drug Administration has handed down some surprising defeats in recent months, and this isn't a slam-dunk case after Pfizer
Interested in more info on MannKind? Add it to your watchlist.
Fool contributor Travis Hoium does not have a position in any company mentioned. You can follow Travis on Twitter at @FlushDrawFool, check out his personal stock holdings or follow his CAPS picks at TMFFlushDraw.
Pfizer is a Motley Fool Inside Value pick. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.